Document is current
Any future updates will be listed below
-
Authors
Sun, Xiujie
Wu, Bogang https://orcid.org/0000-0003-1654-198X
Chiang, Huai-Chin https://orcid.org/0000-0002-7616-3362
Deng, Hui
Zhang, Xiaowen
Xiong, Wei
Liu, Junquan
Rozeboom, Aaron M.
Harris, Brent T.
Blommaert, Eline https://orcid.org/0000-0003-0040-5158
Gomez, Antonio https://orcid.org/0000-0001-5308-981X
Garcia, Roderic Espin https://orcid.org/0000-0003-2494-0964
Zhou, Yufan https://orcid.org/0000-0002-8385-433X
Mitra, Payal
Prevost, Madeleine
Zhang, Deyi
Banik, Debarati
Isaacs, Claudine
Berry, Deborah
Lai, Catherine
Chaldekas, Krysta
Latham, Patricia S. https://orcid.org/0000-0003-2782-9444
Brantner, Christine A.
Popratiloff, Anastas
Jin, Victor X. https://orcid.org/0000-0002-8765-3471
Zhang, Ningyan https://orcid.org/0000-0002-4348-2180
Hu, Yanfen
Pujana, Miguel Angel https://orcid.org/0000-0003-3222-4044
Curiel, Tyler J. https://orcid.org/0000-0001-6962-9411
An, Zhiqiang https://orcid.org/0000-0001-9309-2335
- License Information
-
More Information
Article History
Received: 18 October 2019
Accepted: 22 September 2021
First Online: 3 November 2021
Competing interests
: X.S., H.D., N.Z., Z.A. and R.L. are co-inventors of a pending patent application (62/949,300) filed by the University of Texas Health Science Center at Houston on the anti-DDR1 antibodies described in this manuscript. The University of Texas System and The George Washington University have licensed the patent to Parthenon Therapeutics for drug development. R.L. receives stock option and financial compensation for his role as a member on the Scientific Advisory Board of Parthenon Therapeutics.
